Trial Profile
A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Nivolumab/relatlimab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Gimeracil/oteracil/tegafur; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 12 Feb 2024 Status changed from active, no longer recruiting to completed.
- 30 Nov 2023 Planned End Date changed from 1 Dec 2024 to 12 Jan 2024.
- 16 Nov 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.